Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People Living With HIV Receiving Antiretroviral Therapy

Next Previous
Search
Trial Profile

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People Living With HIV Receiving Antiretroviral Therapy

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenacapavir (Primary) ; Lenacapavir (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 15 Apr 2025 Planned initiation date changed to 20 Apr 2025.
    • 27 Mar 2025 Planned initiation date changed from 26 Mar 2025 to 1 Apr 2025.
    • 21 Mar 2025 Planned initiation date changed from 18 Mar 2025 to 26 Mar 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top